Epitel

Epitel operates at the intersection of wearable medical devices, remote patient monitoring, neurological diagnostics, and applied AI. Its core offering combines the REMI Remote EEG Monitoring System with REMI Mobile, REMI Cloud, and REMI Vigilenz AI for Event Detection. The platform is differentiated by a wireless wearable form factor, remote access to EEG recordings, and sensor operation for up to 30 days, supporting both healthcare facilities and ambulatory settings. This gives Epitel a narrower but potentially more scalable focus than conventional in-hospital EEG equipment, particularly for seizure monitoring outside specialized neurological units. The closest competitive frame includes established EEG and neurodiagnostic device providers, remote-monitoring platforms, and AI-assisted clinical waveform-analysis vendors, but specific competitor names and comparative performance metrics are not sufficiently documented. Epitel’s 2026 partnerships with Stratus and INVI MindHealth suggest an effort to expand beyond device sales into care-access and research workflows.

Epitel’s growth trajectory shows a long development period followed by increasing financing and commercialization activity. The company was founded in 2014 and received two National Institutes of Health grants totaling $7.8 million in 2014 and 2016, supporting early technology development. It then raised a $100,000 venture round in 2019 and a $12.5 million Series A in 2022, with Catalyst Health Ventures and Genoa Ventures among the lead investors. A further $3.12 million venture round in March 2025 preceded the company’s largest financing: a $26 million Series B announced on Jul 28, 2026. The cumulative funding total of $49.52 million reflects a transition from grant-supported research toward scaled medical-device commercialization. Leadership also shifted in February 2025, when Steve Pacelli became CEO and Mark Lehmkuhle moved toward the CTO role, potentially separating commercial execution from technical stewardship. The August 2026 partnerships with Stratus and INVI MindHealth indicate expansion into broader patient-access and research use cases. Available employee data places Epitel in the 11–50 employee range, but there is no quantified hiring trend or revenue information.